Brief: Sensorion Sa Cash Position Of Eur 50 Million At Year-End

Sensorion SA

28/04/2022 06:43

April 28 (Reuters) - Sensorion SA  ALSEN.PA :
    * SENSORION FULL-YEAR 2021 FINANCIAL RESULTS AND BUSINESS
HIGHLIGHTS
    * ACCELERATING DEVELOPMENT OF THE OTOF-GT AND GJB2-GT GENE
THERAPY
PROGRAMS IN COLLABORATION WITH INSTITUT PASTEUR
    * ADVANCING SENS-401 JOINT CLINICAL DEVELOPMENT PROGRAM WITH
COCHLEAR LTD. FOR HEARING PRESERVATION IN PATIENTS SCHEDULED FOR
COCHLEAR IMPLANTATION WITH FIRST PATIENT ENROLLMENT EXPECTED BY
MID-2022
    * SENSORION WILL CONTINUE THE PROOF-OF-CONCEPT CLINICAL
STUDY FOR
CISPLATIN-INDUCED OTOTOXICITY FOLLOWING A THOROUGH ANALYSIS OF
THE SECONDARY ENDPOINTS OF THE AUDIBLE-S SENS-401 STUDY
    * CASH POSITION OF EUR 50 MILLION AT YEAR-END PROVIDES
EXTENDED
CASH RUNWAY UNTIL END OF Q2 2023
    * INTENDS TO FILE A CLINICAL TRIAL APPLICATION (CTA) FOR
OTOF-GT
IN H1 2023
    * END-DEC 2021 NET LOSS EUR 15.2 MILLION VERSUS LOSS OF EUR
9.0
MILLION YEAR AGO
    * IN H1 2022, THE COMPANY EXPECTS TO RECEIVE APPROVAL FOR
THE
PROPOSED TRIAL DESIGN FOR SENS-401 IN PATIENTS SCHEDULED FOR
COCHLEAR IMPLANTATION FROM REGULATORY AUTHORITIES IN AUSTRALIA
AND FRANCE
    * FY OPERATING INCOME EUR 4.3 MILLION VERSUS EUR 2.4 MILLION
YEAR
AGO
    * IN H2 2022, CTA FOR SENS-401 IN CIO WILL BE SUBMITTED
    * END-DEC 2021 CASH AND CASH EQUIVALENTS EUR 50 MILLION
VERSUS EUR
62.2 MILLION YEAR AGO

Source text for Eikon:  ID:nBwbsX8D6a 
Further company coverage:  ALSEN.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))